Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 47Neoplasm Metastasis 9Neoplasms 8Prostatic Neoplasms 7Brain Neoplasms 7Endometrial Neoplasms 6Glioblastoma 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Head and Neck Neoplasms 4Meningioma 3Carcinoma, Renal Cell 3Sarcoma 2Recurrence 2Pancreatic Neoplasms 2Osteosarcoma 2Oligodendroglioma 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Liposarcoma 2Hematologic Neoplasms 2Glioma 2Breast Neoplasms, Male 2Breast Diseases 2Breast Cancer Female 2Venous Thromboembolism 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Unilateral Breast Neoplasms 1

Interventions

lutetium Lu 177 dotatate 5copper dotatate CU-64 3Magnetic Resonance Spectroscopy 3lanreotide 2gallium Ga 68 dotatate 2Nivolumab 2Lutetium-177 2Lutetium 2Ga(III)-DOTATOC 2Carboplatin 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2zimberelimab 1regorafenib 1pembrolizumab 1pasireotide 1irinotecan sucrosofate 1folfirinox 1cabozantinib 1abemaciclib 1X-Rays 1Temozolomide 1Somatostatin 1Resveratrol 1Radiosurgery 1Octreotide 1Ipilimumab 1Granulocyte Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Filgrastim 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gastro-enteropancreatic neuroendocrine tumor × abemaciclib × Clear all
NCT03891784 2026-01-14

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

University of Washington

Phase 2 Active not recruiting
20 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡